2ⁿᵈ Edition of the Cancer R&D World Conference 2026
Scientific Sessions
Trends in Antibody Drug Conjugates (ADCs)
Antibody-drug conjugates (ADCs) are changing the face of targeted cancer therapy through the conjugation of targeted monoclonal antibodies to potent cytotoxic therapies. This advancement allows for the selective targeting of therapeutic agents such as chemotherapy directly to tumor cells while minimizing damage to healthy cells. Recent breakthroughs in linker chemistry, payloads, and target selection have led to greater efficacy, stability, and safety evaluations in ADCs to date. Notably, ADCs have demonstrated improved efficacy across a range of malignancies, including hematological and solid tumors, suggesting an expansion of their role across oncology.
At the Cancer Research and Development Conference 2026, this session will present exciting new trends in the further advancement and evolution of ADC technology. Leaders in the field will discuss progress in conjugation measures, mechanisms of resistance, and combinations with other therapeutic agents. Please join us to hear how ADCs will be leading us into the next era of precision oncology with therapeutics that in addition to targeted delivery will have a biologic impact.
Related Sessions
We, the Precision Global Conferences, welcome all the students, scholars, researchers, and delegates across the globe to patronize their presence at the& ...
Read More>>
Organizer
